Development of a Multiplex Assay to Assess Activated p300/CBP in Circulating Prostate Tumor Cells

The authors examined whether circulating tumor cells (CTCs) identified patients with altered p300/CBP acetylation. CTCs were isolated from 13 advanced prostate cancer patients using Exclusion-based Sample Preparation technology.